financetom
Business
financetom
/
Business
/
Funko Stock Climbs On Better-Than-Expected Q4 Results
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Funko Stock Climbs On Better-Than-Expected Q4 Results
Mar 7, 2024 2:38 PM

Funko ( FNKO ) shares are climbing after the company reported its fourth-quarter financial results after the bell. Here's a look at the highlights. 

The Details: Funko ( FNKO ) reported quarterly earnings of 1 cent per share which beat the analyst consensus estimate of losses of 4 cents per share.

Quarterly sales came in at $291.2 million, beating the analyst consensus estimate of $281.961 million by 3.28%. Inventory levels were lowered to $119.5 million on Dec. 31, 2023, versus $246.4 million from the prior year.

The company announced Steve Nave, Funko’s CFO and COO, will resign effective March 15. Yves LePendeven, the company’s deputy CFO, will serve as acting CFO as of the same date.

“In 2023, we implemented a comprehensive plan to significantly reduce costs, improve operational efficiencies and focus on our core product offerings,” said Michael Lunsford, Funko’s Interim CEO.

“The major elements of that plan, which addressed the company’s inventory issues, unprofitable product lines and SKUs, workforce size, and several other factors, were successfully completed, and we believe our company is now on a significantly more solid foundation upon which we intend to build and grow,” Lunsford said.

Outlook: Funko ( FNKO ) sees first-quarter net sales of between $214 million and $227 million and fiscal year 2024 net sales between $1.047 billion and $1.103 billion.

FNKO Price Action: According to Benzinga Pro, Funko ( FNKO ) shares are trading up 12.58% after-hours at $7.25 at the time of publication Thursday.

Related News: MongoDB Stock Tumbles After Q4 Performance – Here’s Why

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Invivyd Names Jeremy Gowler as Interim CEO
Invivyd Names Jeremy Gowler as Interim CEO
Apr 12, 2024
10:30 AM EDT, 04/12/2024 (MT Newswires) -- Invivyd ( IVVD ) said Friday that Jeremy Gowler was named interim chief executive officer, effective immediately, succeeding Dave Hering. Gowler, 47. will remain as chief operating officer and chief commercial officer while serving in the interim position with the board looking for a permanent CEO, the company said in a regulatory filing....
Harmonic Says VOS Media Software Gets Red Hat OpenShift Cloud-Native Network Function Certification
Harmonic Says VOS Media Software Gets Red Hat OpenShift Cloud-Native Network Function Certification
Apr 12, 2024
10:40 AM EDT, 04/12/2024 (MT Newswires) -- Harmonic (HLIT) said Friday its VOS Media Software achieved Red Hat OpenShift cloud-native network function certification. Red Hat OpenShift allows users to deploy video streaming and broadcast applications faster through reduced operational costs, Harmonic said. The company said that media companies and service providers can now deploy any VOS Media Software-powered video streaming...
AbbVie Says Phase 3 Interim Data Support Long-Term Efficacy, Safety of Migraine Drug
AbbVie Says Phase 3 Interim Data Support Long-Term Efficacy, Safety of Migraine Drug
Apr 12, 2024
10:43 AM EDT, 04/12/2024 (MT Newswires) -- AbbVie ( ABBV ) said Friday that interim data from an ongoing phase 3 extension study support the long-term safety, tolerability and efficacy of atogepant 60 mg to prevent chronic and episodic migraine. The company said 70% of the participants experienced at least 50% fewer migraine days each month after 13 to 16...
Novo Nordisk/Eli Lilly's Weight Loss Drugs Does Not Cause Suicidal Behaviors - After FDA, European Medicines Agency Says
Novo Nordisk/Eli Lilly's Weight Loss Drugs Does Not Cause Suicidal Behaviors - After FDA, European Medicines Agency Says
Apr 12, 2024
The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) has determined that there is no substantial evidence supporting a link between Glucagon-Like Peptide-1 receptor agonists (GLP-1) and suicidal or self-injurious thoughts and behaviors.  The assessment comes following reports of suicidal thoughts or actions. The FDA also conducted a review of GLP-1 RAs. The FDA released an update stating that its preliminary review did...
Copyright 2023-2026 - www.financetom.com All Rights Reserved